Podcasts about CNS

Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months.We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of Step Pharma and Gene Mack of Gain Therapeutics, and the unlikely paths that got them there. We'll dig into the science of nonsense mutations with Nerissa Kreher of Alltrna, circular RNA with Lu Gao of Therorna, and a cancer target hiding in human genetics. And we'll close with what these leaders think success actually looks like, years from now.So sit back, and let's revisit some of our favourite moments from the summer.02:32 Solving the delivery problem08:39 Founder journeys15:13 Platform science24:41 Business, money, and geopolitics32:28 Looking aheadInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Episode 204: The first PROTAC is here. What comes next in protein degradation?Episode 205: Turning cancer cell dependencies into targeted therapiesEpisode 208: Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson'sEpisode 209: Why Western pharma is sleeping on China's circular RNA revolutionEpisode 211: Beyond biology: Nanobiotix's physics-first approach to cancerEpisode 213: How Evox Therapeutics is targeting CNS diseases with exosomesEpisode 214: Rewriting the rules of genetic medicine with tRNA therapeutics

In this Supplement Stack Series episode, Nurse Doza breaks down the MTHFR gene — the enzyme behind methylation, detoxification, neurotransmitter production, and energy — and explains why the form of folate you take matters if you carry one of the common variants. He walks through The MTHFR Stack by MSW Nutrition: the methyl donors, the methylated B vitamins, and the liver support that keep the methylation cycle turning. If methylation is your bottleneck, start here. FEATURED PRODUCT The MTHFR Stack by MSW Nutrition bundles the three formulas Nurse Doza reaches for when methylation support is the goal — Bliss, Boost, and Liver Boost — into one system. Together they cover the methyl donors (betaine/TMG and SAMe), the methylated B vitamins (methylfolate, methylcobalamin, B6 as P-5-P) and glutathione, and the phase II liver pathway where methylation and detoxification meet. Rather than supporting one step and starving the next, the stack works the whole cycle.

Listen Online: About this episode: In this episode of The First Lady of Nutrition Podcast, we talk about Juvent, a very unconventional vibration plate, with Rush Simonson, the company’s CEO. Unlike traditional vibration plates that vigorously shake the body, Juvent delivers very small, low-force vertical signals, just 0.3 to 0.4 g with about 0.05 mm of movement. The platform also measures the user and automatically adjusts within a 32–37 Hz range to find that person’s resonant frequency. Simonson explains why these differences matter and discusses research on low-magnitude mechanical stimulation and bone density, including a randomized clinical trial involving childhood cancer survivors. You’ll also hear why running shoes may not always be the best choice for walking, what women should know about DEXA scans before and after menopause, and how bones respond to mechanical stimulation. Ann Louise and Rush also discuss the somatopsychic effect, the idea that changes in the body can influence the brain, as well as research into the broader effects of micro-impact on the body. If you’re concerned about maintaining strong bones as you age, this conversation offers a fascinating look at an approach you may not have heard much about. Learn more about Juvent at annlouise.com/juvent. Save $500 on a Micro-Impact Platform with code ALG.The post Vibration Plates for Bone Density: What Really Works? first appeared on Ann Louise Gittleman, PhD, CNS.

E Mëttwoch war ënnert anerem de Clinch tëscht AMMD, CNS a Regierung Theema an der Emissioun "Invité vun der Redaktioun".

Most conversations about nutrition begin with what is on the plate. This one begins much farther upstream—with the soil, the grass, the animal, and the way our food is raised.In this episode of the Homesteaders of America Podcast, Amy speaks with Julia Mitchell, MSc, CNS, LDN, a clinical nutritionist, grass-fed bison rancher, mother of two, and Lead Educator for Ancestral Supplements. Julia shares how a desire to become more capable and connected to her food led her from a regional food hub to bison ranching in southwestern Alberta—and how working with the land has reshaped her understanding of human nourishment.Together, they discuss what nutrient density actually means, why the quality of our food begins in living soil, and how modern agriculture's focus on yield can leave nutrition behind. Julia also explains why traditional cultures valued the whole animal, what liver and other organ meats can add to the family diet, and simple ways homesteaders can make those foods less intimidating—from blending liver into ground meat to using bones, marrow, connective tissue, and slow-cooked cuts.The conversation also explores where whole-food supplements may serve as a practical bridge, what consumers should know about sourcing and third-party testing, and why no capsule can replace the deeper work of rebuilding food skills, supporting responsible farmers, and understanding where nourishment comes from.This episode is an invitation to think more deeply about food—not merely as calories or protein, but as the product of healthy soil, careful stewardship, practical knowledge, and a resilient family culture.In This Episode, We DiscussHow Julia moved from city life and a regional food hub into grass-fed bison ranchingWhat makes raising and handling bison different from raising cattleWhy nutrition begins with soil—and why food quality cannot be separated from land healthWhat “nutrient density” means beyond marketing languageHow farming for yield can dilute the vitamins and minerals in foodWhy organ meats fell out of favor and what was lost when they disappeared from the family tableHow nose-to-tail eating honors the animal and broadens the nutrient profile of the dietA simple way to ask your butcher to blend liver into ground meatWhy liver is so nutrient-dense and why it should not be misunderstood as a storage tank for toxinsWhere food-first nutrition ends and whole-food supplementation may beginHow freeze-drying preserves organ meats for capsules or powdersWhat third-party testing and careful sourcing should addressWhy practical food skills are essential to family resilience and self-sufficiencyWhy bison ranchers are, at heart, grass farmers—and why protecting grasslands mattersAbout Julia MitchellJulia Mitchell, MSc, CNS, LDN, is a clinical nutritionist, bison rancher, mother of two, and Lead Educator for Ancestral Supplements. Her work sits at the intersection of functional nutrition, ancestral health, regenerative agriculture, and optimal health. Shaped by both her clinical nutrition work and her hands-on experience raising grass-fed bison on a regenerative ranch in southwestern Alberta, Julia is especially knowledgeable about nose-to-tail eating, organ meats, animal-based nutrition, and making nutrient-dense whole foods approachable for modern families.Links and Resources MentionedAncestral Supplements — ancestralsupplements.comThe Self-Sufficient Life and How to Live It by John SeymourSavory Institute and holistic management principles — savory.globalVISIT HOA ONLINE at homesteadersofamerica.comDISCLAIMER: This episode is for general educational purposes only and is not individualized medical or nutrition advice. Nutrient needs and supplement safety vary. Consult a qualified healthcare professional before making significant dietary changes or using concentrated supplements, especially during pregnancy, for children, when taking medications, or when managing a medical condition.

Sciatica comes from the sciatic nerve, right… Right?This episode of the Unreal Results podcast was inspired by a recent conversation with a friend of mine who had self-diagnosed herself with sciatica. And while sciatica is often given as a diagnosis, it's actually more of a description of symptoms than anything else. In this episode, you'll hear how I actually think through sciatica and why those symptoms can have very different drivers beyond the sciatic nerve or lumbar spine.In This Episode, You'll Learn:How to differentiate between several potential drivers of sciatica-like symptomsWhere visceral, peripheral neurovascular, and CNS influences fit into your assessmentHow I use the symptom presentation and the LTAP® to narrow down the potential driverOdds are high that someone with sciatica symptoms is going to walk into your practice. This episode will give you a more connected framework for thinking through what to assess and ultimately, what to treat.Resources & Links Mentioned In This Episode:Get on the waitlist for the next cohort of the online LTAP® Level 1 courseEp. 9: Left Side Sciatica or Right Side Shoulder Pain?Ep. 27: Sciatica SecretsEp. 48: Small Intestine and Mesenteric RootsEp. 157: The Visceral Connection to Musculoskeletal PainCheck out the Swelling Reduction Protocol Course Here!Learn the LTAP® In-Person in one of my upcoming coursesThe Missing Link in Orthopedic Rehab: 2-part virtual trainingLearn how ONE change to your assessment can get your clients better results, faster.

The blood–brain barrier is a highly specialised interface that regulates the movement of cells, molecules and nutrients between the circulation and the central nervous system. But what happens when this critical barrier becomes dysfunctional in multiple sclerosis? In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Elga de Vries of Amsterdam UMC and MS Center Amsterdam about the evolving science of blood–brain barrier dysfunction in MS. They explore how the blood–brain barrier functions in health, how its disruption relates to immune cell infiltration and inflammatory disease activity, and why research increasingly suggests these changes may remain relevant across different stages of MS. The conversation also looks at innovative blood–brain barrier-on-a-chip models, how existing MS treatments interact with the barrier, and emerging approaches designed to transport therapies more effectively into the CNS. Finally, they consider an intriguing future direction: could strengthening the blood–brain barrier itself become part of the therapeutic strategy for MS? This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Roche, Sanofi, and UCB.

The people grinding hardest for their health are often the ones training themselves into breakdown. What if the endurance work you trust most is the very thing wrecking your heart?Mark Sisson is the founder of Mark's Daily Apple, Primal Kitchen, and Peluva, and one of the original architects of the ancestral health movement. He's a former elite endurance athlete who, at 73, now argues that the training that built his name nearly wrecked his heart. We talked about the minimum effective dose: why most people should stop running, how diet drives 80% of your results, and why your feet may be the most overlooked lever in staying strong for life.What we explore:- Why most people should stop running, and how endurance training drives overtraining and CNS stress.- How chronic cardio contributed to Mark's heart arrhythmias, common among lifelong endurance athletes.- What metabolic flexibility is, and why diet drives 80% of body composition.- Why foot health is the overlooked key to longevity and fall prevention.- How to tell a hack worth doing from biohacking noise.Chapters:00:00 How to Get Healthy Without Chasing It03:36 Why You Retire and Don't Feel Good05:50 The Health Pillars Nobody Talks About08:19 How to Build Metabolic Flexibility11:51 The Minimum Effective Dose for Fitness15:20 How to Read Your Blood Work19:01 Signs You're Overtraining Your Nervous System24:33 Get Ideal Body Composition With Less Effort31:39 Why Most People Should Not Run37:26 Why Foot Health Is the New Sleep41:41 How Modern Shoes Destroy Foot Function48:43 What Your Feet Do Barefoot on Sand58:07 Why You Should Walk Backwards59:27 How to Cut Through Biohacking Noise01:07:40 Why High-Tech Shoes Won't Save You01:22:22 The One Habit That Beats EverythingAbout Mark Sisson:Mark Sisson is a former elite endurance athlete turned health educator and entrepreneur, author of Mark's Daily Apple and founder of Primal Kitchen and Peluva. At 73, he's one of the most credible voices on eating, training, and recovering for a long, strong life.Connect with Mark Sisson:Instagram: https://www.instagram.com/marksissonprimalSubstack: https://www.marksdailyapple.comNewsletter: https://marks-newsletter-4655f1.beehiiv.comGet your Peluva shoes here for barefoot freedom:

In this episode of *PICU Doc on Call*, Drs. Pradip Kamat and Rahul Damania dive into the topic of beta-blocker toxicity. They walk through a case of a 15-year-old who comes in with bradycardia, hypotension, hypoglycemia, and altered mental status after an intentional ingestion. Using a board-style question, they break down how to tell the difference between beta-blocker and calcium channel blocker poisoning and review key points about cardiac physiology and receptor signaling.Drs. Kamat and Damania discuss management strategies, including glucagon, high-dose insulin therapy, vasopressors, calcium, and ECMO as a last resort. They also spend some time focusing on specific agents like propranolol and sotalol, highlighting what makes their toxicologic profiles unique. This is a high-yield episode packed with pearls for pediatric intensivists!Show Highlights:Clinical case of a 15-year-old patient with bradycardia and hypotension due to intentional drug ingestionBeta-blocker toxicity and its clinical featuresDifferentiation between beta-blocker and calcium channel blocker toxicityKey physiological concepts related to cardiac action potentials and beta receptor functionClinical presentation and diagnostic workup for beta-blocker toxicityManagement strategies for beta blocker overdose, including airway control and fluid resuscitationSpecific toxicologic profiles of common beta-blockers (e.g., propranolol, sotalol, metoprolol)Importance of recognizing hypoglycemia and CNS effects in beta-blocker toxicitySummary of critical management steps and take-home points for pediatric intensivistsEncouragement for further learning and engagement on related topicsReferences:Fuhrman & Zimmerman - Textbook of Pediatric Critical Care Chapter 126. Toxidromes and their treatment. Joshi P. Pages 1504-1505Reference 1: Rogers textbook of Pediatric Intensive Care: Chapter 36: Poisoning. Nares M, Jeyapalan A, Weisman R: pages 525-543Reference 2: Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR; American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. doi: 10.1161/CIR.0000000000001161. Epub 2023 Sep 18. PMID: 37721023.Suarez F, Koyfman A, Long B. Pearls and Pitfalls for the Emergency Clinician: Beta Blocker and Calcium Channel Blocker Toxicity. J Emerg Med. 2026 May;84:1-11. doi: 10.1016/j.jemermed.2026.01.021. Epub 2026 Jan 27. PMID: 41833262.

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Steven Kao, Medical Oncologist at Chris O'Brien Lifehouse, is joined by A/Prof Venessa Chin, Medical Oncologist at St Vincent's Hospital and Researcher at the Garvan Institute of Medical Research, and Dr Ben Kong, Medical Oncologist at Prince of Wales Hospital. Together, they explore the clinical features of ROS1-positive non-small cell lung cancer, the evolving diagnostic and treatment landscape in Australia, and how the recent PBS listing of repotrectinib is influencing first-line treatment decisions. The discussion also covers CNS disease, treatment sequencing, resistance mechanisms, and emerging therapies that may further improve outcomes for patients. This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Introduction, Host Welcome & Acknowledgement of Country (01:33) The "Unicorn" Mutation: Clinical Characteristics & Prevalence (03:22) Diagnostic Testing: IHC, FISH vs. Gold Standard NGS (05:15) Clinical Red Flags: High Thromboembolic Risk & CNS Predilection (08:18) Treatment Landscape in Australia: Crizotinib, Entrectinib, Repotrectinib (10:11) Managing Unique Repotrectinib Side Effects (Dizziness, Dysgeusia, Ataxia) (13:42) Intracranial Response & Choosing First-Line TKIs (19:20) Post-TKI Progression Strategies: Biopsy, Chemo-IO, & Local Stereotactic Radiotherapy (SRS) (26:15) The Horizon: Emerging Next-Generation TKIs & Resected ROS1 Disease (29:05) Closing Remarks ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Full shownotes, transcript, and resources here: https://soundbitesrd.com/317                              Disclosure: This episode is sponsored by General Mills Bell Institute of Health and Nutrition and offers 1 Free continuing education credit for RDNs. See more details below. The Whole Grain Gap: Benefits, Myths and Easy Ways to Eat More Whole grain recommendations – and the science behind them – have remained remarkably consistent for decades, yet only two percent of Americans are getting enough. In today's wellness and social media landscape, carbohydrates and grain foods are often oversimplified, misunderstood or unfairly vilified. Yet, consumers are actively seeking many of the benefits whole grain foods support, including fiber intake, gut health, cardiometabolic health, satiety, and overall diet quality. This podcast episode explores the disconnect between the perception of grain foods and the reality of what they offer, discussing the science behind recommendations, as well as the challenges people face when it comes to getting the recommended intake. Listeners will learn from nutrition experts on how they can help close the whole grain gap by leveraging insights and accessible strategies. Whether you're looking to understand the latest research or get practical tips for bringing whole grains back into the nutrition conversation (and your diet), this episode delivers evidence-based, real-world tips to transform your approach to whole grains.  Tune in to learn more about:  definition of whole grains and their components health benefits of whole grains including disease risk reduction common misconceptions and confusion about grains how to understand food labeling strategies for increasing whole grain intake in daily life the impact of trends like low-carb and high-protein diets on grain consumption emerging research on gut health and antioxidants in whole grains practical tips for food shopping and meal planning resources for health professionals and the public This episode awards 1.0 Free CPEU in accordance with the Commission on Dietetic Registration's CPEU Prior Approval Program. Commercial support has been provided by General Mills Bell Institute of Health and Nutrition. Alex Turnbull, RDN, LD and Julie Miller Jones, PhD, LN, CNS, CFS, FAACCI, FICC have each received an honorarium for their time to participate in the podcast interview. Any opinions or scientific interpretations expressed during this episode are those of the guests and do not necessarily reflect the position or policy of General Mills.   

Listen Online: About this episode: The First Lady of Nutrition, Ann Louise Gittleman, sits down with Dr. Michael Biamonte, author of The Candida Chronicles, for an eye-opening conversation about the growing concern over Cyclospora and what you need to know to protect yourself. Dr. Biamonte explains why this stubborn intestinal parasite can be so difficult to eliminate, the symptoms that should send you straight to your doctor, why simply rinsing produce may not be enough, and what he believes may help when common antiparasitic approaches fall short. However, removing an intestinal invader may be only part of the story. What happens to the delicate balance of bacteria and yeast in your gut afterward? That's where the conversation turns to Candida, an area Dr. Biamonte has studied and treated for decades. He explains the often-overlooked connections between parasites, bacteria, and Candida; why he believes so many Candida cases are treated incorrectly; which tests can reveal what's really happening in the gut; and why diet and specific herbs can be important pieces of the puzzle. Ann Louise and Dr. Biamonte also discuss the significance of stool pH, why Candida and harmful bacteria sometimes need to be addressed together, recurring Candida problems following COVID, his thoughts on spike protein and Hashimoto's, and even a fascinating traditional remedy for thrush. If you've struggled with unexplained digestive issues, recurring Candida, parasites, or a gut that simply doesn't seem to get back on track, this information-packed episode connects some dots you may never have considered. To learn more about Dr. Biamonte and his work, visit https://health-truth.com/.The post Cyclospora: The Parasite Making Headlines & the Candida Connection   first appeared on Ann Louise Gittleman, PhD, CNS.

MAPS BOGO: https://mapsbogo.com Buy one get one free — mix and match any of the top 10 most popular programs (Anabolic, Aesthetic, Performance, 15 Minutes, Anywhere, Symmetry, Starter, Muscle Mommy, Powerlift, 40+) for $157.   In this episode the guys break down whether a good gym actually makes a difference — covering convenience, cleanliness, and culture as the three things the gym industry has identified as the real drivers of consistency. They cover why 24 Hour Fitness put gyms within ten miles of each other on purpose, why culture matters more than equipment, why CrossFit proved that a grimy box with no air conditioning can beat a fully equipped luxury gym, and why the right culture depends entirely on where you are in your fitness journey. They also get into new probiotic research showing measurable effects on strength, endurance and fat loss through improved amino acid availability, gut wall permeability in athletes, and CNS firing efficiency, why gluten sensitivity is more common than people realize and how to know if it's affecting your results, the famous Nun Study from the 1980s showing nuns with full Alzheimer's pathology who still scored perfectly on cognitive tests, why their voices have all gotten lower over ten years of podcasting, and the new Mind Pump Hormones community on Skool replacing their Facebook forum. Then they answer questions from Instagram.   MP Hormones Skool Community (free): https://skool.com/mindpumphormones Moderated peptide and hormone therapy discussion with medical professionals.   SPONSORS   Seed Daily Synbiotic: https://seed.com/mindpump Code: 25MINDPUMP for 25% off your first month. Probiotics discussed on air — emerging data on strength gains, endurance and fat loss through gut health optimization.   Hiya (kids' multivitamin): https://hiyahealth.com/MINDPUMP 50% off first order. Zero sugar, non-GMO, vegan, allergy-free. The only kids multivitamin the guys recommend.   LINKS   Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia   0:00 - Intro 1:46 - Does a good gym actually make a difference? 8:48 - The three things that predict gym consistency: convenience, cleanliness and culture 11:06 - Why CrossFit proved culture beats equipment every time 17:43 - Why the right culture depends on where you are in your journey 23:12 - Why Orange Theory consistency is worth celebrating before evolving 27:27 - New probiotic research showing measurable effects on strength, endurance and fat loss 31:05 - Leaky gut is more common in athletes than the general public — why 34:10 - How gluten sensitivity shows up as low-level systemic inflammation without you realizing it 45:32 - The famous Nun Study — brains full of Alzheimer's pathology, perfect cognitive scores 59:34 - Mind Pump Hormones community is moving from Facebook to Skool 1:02:20 - Q&A: How to progress in a squat when you're already strong and in a deficit 1:05:04 - Q&A: Traditional sauna vs. infrared — which one has the science behind it? 1:08:13 - Q&A: If muscles grow through rest, how do bodybuilders train 6-7 times a week? 1:12:55 - Q&A: How long should you give a calorie deficit before expecting to see results?

“The microbiome world is moving from supplementation towards ecosystem restoration.” - Danielle ArnoldFor a long time, the functional medicine approach to gut health focused on getting rid of what shouldn't be there. It was all about finding the overgrowth, using antimicrobials, adding probiotics, and rebuilding. Those tools are still useful, but our understanding of the microbiome has become much more sophisticated. Now, we can think about restoring the gut's ecosystem, including the keystone species that help create an environment where beneficial bacteria can thrive, and opportunistic bacteria have a much harder time taking over.With the complex clients we see as women's health practitioners, this shift becomes especially important. Someone with endometriosis, histamine intolerance, MCAS, long COVID, metabolic dysfunction, or significant digestive symptoms may not be able to jump straight into eating 45 grams of fiber a day. Sometimes we have to work in a very specific order, supporting digestion, reducing overgrowth, rebuilding beneficial species, and then gradually giving those microbes the fibers and polyphenols they need. The goal is not simply a better stool test. It's a more resilient gut ecosystem that can better support the immune system, nervous system, hormone health, and the rest of the body.In today's episode, I'm joined by Dr. Oscar Coetzee and Danielle Arnold, CNS, from Designs for Health for a wonderfully nerdy conversation about what we now know about rebuilding the gut microbiome. We talk about new research on keystone species like Akkermansia, Faecalibacterium, and Roseburia, how these microbes work together, when antimicrobials may still be useful, why the order of treatment matters for sensitive clients, histamine and hormone health, H. pylori, digestive function, fiber and polyphenols, stool testing, how better gut microbiome support can become part of our clinical thinking, and more.Enjoy the episode, and let's innovate and integrate together!---Learn more or watch the video version of this conversation at https://integrativewomenshealthinstitute.com/how-to-rebuild-a-healthy-gut-microbiome-with-dr-oscar-coetzee-and-danielle-arnold/.Connect with me and access our entire platform at IntegrativeWomensHealthInstitute.com (https://integrativewomenshealthinstitute.com/).Find and follow us @integrativewomenshealth on YouTube (https://www.youtube.com/@integrativewomenshealth) and Instagram (https://www.instagram.com/integrativewomenshealth/).

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) CEO Anthony Tennyson spoke with Proactive's Stephen Gunnion about the company's £1.3 million fundraising and how proceeds will support its CNS pipeline, spanning SVN-001, SVN-002 and SVN-015. Tennyson said the funding will let Solvonis assess adding international sites to the Phase 3 programme for SVN-001, its severe alcohol use disorder treatment being trialled within the UK's NHS. Including EU sites and data could improve prospects for a European launch or make the programme more attractive to partners. On SVN-002, developed for moderate to severe alcohol use disorder in the US, the company is repurposing esketamine as an oral thin film via the FDA's 505(b)(2) pathway, building a scientific bridge to Johnson & Johnson's Spravato. Discussions with the FDA continue, with Tennyson saying next steps will "hopefully" involve a small toxicology package ahead of a Phase 2 or possible Phase 2b trial. The interview also covered SVN-015, Solvonis' proprietary compound targeting methamphetamine and cocaine addiction, with the US National Institute on Drug Abuse now funding further preclinical work following positive initial screening data. On wider industry interest, Tennyson said: "There are strong tailwinds for the CNS, psychedelics and psychedelic-adjacent industry." Visit Proactive's YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #SolvonisTherapeutics #SVN001 #SVN002 #SVN015 #CNS #Biotech #Pharmaceuticals #DrugDevelopment #AlcoholUseDisorder #AddictionTreatment #Neuropsychiatry #ClinicalTrials #Phase3 #FDA #NIDA #BiotechInvesting #LifeSciences #ProactiveInvestors

Den CNS-President seet an der Press, datt d'CNS ni gesot hätt, datt d'Doktere "Schummler" wieren, mee si missten hir Proposen op de richtege Plaze virdroen

In this episode of BioTalk with Rich Bendis, Matt Adams, Chief Executive Officer of BrainScope, joins the conversation to discuss how the Rockville-based company is working to bring objective brain function measurement into real-world clinical care.   Matt shares how BrainScope is using EEG-based technology and artificial intelligence to help decode brain electrical activity and provide clinicians, patients, and care teams with simple, actionable information. He explains why objective data is especially important in brain health, where many assessments can still be subjective, difficult to scale, or dependent on more expensive infrastructure.   The conversation also looks at BrainScope's evolution since winning the BioHealth Capital Region Crab Trap Competition in 2020. Matt discusses how the company has moved from a point-of-care EEG technology focused on traumatic brain injury into a broader AI-enabled brain health platform with potential applications across concussion, brain bleeds, dementia, Alzheimer's disease, and other neurological conditions.   Rich and Matt also discuss BrainScope's FDA-cleared technology, its growing clinical and regulatory foundation, and how the company is using machine learning, deep learning, and a large EEG database to expand what can be measured in brain health. Matt highlights the company's work in Alzheimer's prediction, including data suggesting the potential to identify risk years before typical clinical diagnosis, as well as the opportunity to support longitudinal monitoring and improved CNS trial design.   The episode also looks ahead to BrainScope's next phase, including expanded disease applications, partnerships with clinicians and sports medicine organizations, potential use in clinical trials, global market opportunities, and the company's continued growth in the BioHealth Capital Region.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Matt Adams brings more than 25 years of global healthcare leadership experience developing, commercializing, and scaling medical device, biotechnology, diagnostic product, and service businesses. He currently serves as Chief Executive Officer of BrainScope, a tech-enabled AI software platform focused on brain health. Before joining BrainScope, Matt was President of Invio Automation, a global life science-focused process automation provider. He previously served as Vice President and General Manager of Cerevention, a neuro startup that developed and commercialized platforms to diagnose and treat hemorrhagic stroke and other diseases of the central nervous system. He has also held executive roles at Rebiotix, Cirle, and American Medical Systems. Matt received his eMBA from the University of Minnesota, a Master of Science in Biomedical Engineering from the University of Minnesota, and a Bachelor of Science in Mechanical Engineering from the University of Alaska.

"They're really worried that radiation is going to be painful. So they come in for that first day of treatment very anxious. With our patients with brain cancer, we're using the masks on the table, and those masks are very tight and hold their heads very, very still. So they'll be very worried about being claustrophobic. We may start out the first day or two with a little bit of [lorazepam]. And they'll come to me and they'll say, 'This really hasn't been as bad as I thought it was going to be,'" ONS member Catherine McCluskey, BSN, RN, OCN®, ROCN™, radiation oncology staff nurse at Atrium Health Wake Forest Baptist in Winston-Salem, NC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, who was the manager of oncology nursing practice at ONS at the time of the recording, during a conversation about radiation side effects in central nervous system (CNS) cancers. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 21, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat CNS cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Radiation Site-Specific Side Effects series Episode 306: Cancer Symptom Management Basics: CNS Toxicities ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy CNS Survivorship Needs More Research, Funding, and Training, Expert Panel Says Here's What the Updated CTCAE Version 6.0 Means for Oncology Nurses Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: Indications of Targeted Radiotherapy to the Brain and Spine: 2025 ONS Congress® Session ONS ROCN™ Certification Review™ ONS/ONCC® Radiation Therapy Certificate™ Supporting Radiation Side Effect Management Through ONS Evidence-Based Resources: 2025 ONS Congress® Session Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Radiation Necrosis: A Differential Diagnosis Dilemma The Neurocognitive Late Effects of Cranial Radiation Therapy: The Often-Unrecognized Outcomes Oncology Nursing Forum article: Symptom Clusters in Patients With Brain Tumors Undergoing Proton Beam Therapy ONS Huddle Cards: External Beam Radiation Proton Therapy Proton Therapy Radiation ONS Guidelines™ and Symptom Management Resources Cognitive impairment Fatigue Mucositis Radiodermatitis ONCC resources: Big List of CE Radiation Oncology Certified Nurse (ROCN™) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Patient Health Questionnaire (PHQ-9 and PHQ-2) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "With primary tumors—glioblastomas, astrocytoma, all of those types of cancerous primary CNS tumors, the tumors are not very well-defined. They have little tentacles that kind of go out, so doing something like Gamma Knife, which is very precise, is not as effective as an external beam because the external beam will deliver radiation to all those little tentacles that are out there in the brain. And with Gamma Knife, you really can't effectively do that." TS 2:34 "When we're doing radiation to the brain, fortunately there aren't that many acute toxicities involved. Sometimes they'll have some mild dermatitis. Usually, it's not very significant. They, like everyone else who gets radiation, will have fatigue. Usually once we get to the end of the second week of radiation, into the third week for our patients with primary CNS tumors—the hair loss—they'll start to notice hair loss just in the treatment area. But those are typical, the things that we've seen most. Sometimes we'll have patients who will experience some nausea, maybe a few headaches, but really the acute toxicities are not severe typically with our patients with brain tumors." TS 8:30 "[For] the fatigue, I tell patients to just listen to their bodies. We don't want them to be sedentary, and we want them to go out and continue living their lives. But I do warn them that the fatigue is pretty much common to all patients receiving radiation at various degrees, depending on the patient. I just tell them to do what they feel like doing, and then when they're tired to rest, and if they find themselves having a nap in the afternoon, that's okay." TS 13:51 "What I find with these patients in particular is that a lot of times, their first symptoms related to any type of cancer are CNS symptoms from brain metastasis. Our patients with lung cancer or melanoma—they come in through the emergency room for altered mental status or seizures or something like that. They find a mass in their brain, and then they find a mass on their lung, or they find masses everywhere. Typically, they want to treat the brain masses first before they start them on any kind of systemic treatment. And so, they'll come to us, and they're in shock. Everything's happened very quickly. They haven't had a chance to really catch their breath. They're overwhelmed. And so I try to make sure they understand that everyone that they see here is part of their team and is with them through this journey and they're not alone." TS 25:36 "A couple of years ago, ONS put out an email asking for people to volunteer to do a delineation study about the feasibility of doing a radiation oncology certified nursing exam. And I, just on a whim, responded to that email. It's not something I've ever done before, and thinking that I would not be put on the team. … And I thought, 'I don't have enough experience, I don't know what I'm doing, and they won't choose me.' And lo and behold, they put me on this role delineation study. … I have met so many incredible nurses with all kinds of experience. I've learned so much. It has opened up a lot of things for me and it's been really exciting, so all I can do is say take advantage of those opportunities when they come. Don't think that you don't know enough, because you know more than you think you do." TS 32:38 

Listen Online: About this episode: The First Lady of Nutrition welcomes renowned natural health and Ayurveda expert Dr. John Douillard to uncover what thousands of years of ancient wisdom can teach us about living longer, and why modern science is finally beginning to catch up. From the three Ayurvedic body types (Vata, Pitta, and Kapha) to eating with the seasons and working with your natural circadian rhythm, Dr. Douillard explains why some of the smartest longevity “hacks” may not be new at all. Ann Louise and Dr. Douillard also dive into some of today's hottest health topics, including why revving up metabolism later in life may backfire, his concerns about peptides for people with a history of cancer, and why less may be more when it comes to melatonin. Plus, discover the surprising longevity connection between your lymphatic system, nitric oxide, and something most of us do roughly 20,000 times a day: breathe. Dr. Douillard explains why breathing through your nose instead of your mouth can make such a difference—and why he even teaches some of his patients to sleep with their mouths taped shut. Dr. John Douillard, DC, CAP, is a globally recognized leader in natural health, Ayurveda, and sports medicine who has spent decades exploring the science behind ancient healing traditions and translating that wisdom into practical strategies for modern health and longevity. For more information check out LifeSpa.com.The post Ancient Wisdom, Modern Science: Biohacking Longevity with Ayurveda first appeared on Ann Louise Gittleman, PhD, CNS.

In Part 2 of Tara's conversation with Dr. Lindsey Berkson, they continue the discussion by looking at the different forms and delivery methods of HRT, including Bi-Est, estradiol, estriol and progesterone. They discuss why the way a hormone is delivered can matter, why vaginal progesterone may work differently from oral or topical progesterone, and why individual response matters when choosing a delivery method. The conversation then moves into testosterone and breast health, including the role of hormone metabolites and estrogen receptors. Dr. Berkson also shares her thoughts on mammograms and breast cancer screening, including her own experience of finding breast cancer shortly after receiving a negative mammogram. This episode ultimately comes back to one of the biggest themes of the entire conversation: don't blindly follow a protocol simply because it's considered standard. Understand the evidence, understand the limitations, and make informed decisions with appropriate medical support.   In Part 2: Why Tara switched to an estradiol patch Dr. Berkson's history developing menopause supplements Progesterone, puberty and menstrual health Why hormone education is missing from conventional medical training Why Bi-Est? Bringing estradiol and estriol back into the conversation Testosterone, muscle, brain health and breast health Why progesterone delivery needs to be individualised Oral vs vaginal vs topical progesterone How Dr. Berkson approaches mammograms, ultrasound and other screening methods The breast cancer Dr. Berkson discovered after a negative mammogram Why Dr. Berkson created Everything Breast Cancer and her personal mission to help women navigate breast cancer Dr. Lindsey Berkson Lindsey Berkson, MA, DC, CNS, DACBN was a Distinguished Hormone Scholar at the Center for Bioenvironmental Research (CBR: Tulane/Xavier Universities). She is a leading figure in integrative medicine, renowned for her expertise in hormones, nutrition, digestion, and environmental science. With a background as a clinician, professor, bestselling author, and radio show host, she brings a wealth of experience to her work. At the CBR, she collaborated with pioneers in estrogen and sex-steroid receptor research. Dr. Berkson is also a respected educator, teaching MDs and pharmacists in advanced certification courses. She has developed innovative nutraceuticals, holds patents in bioidentical hormone therapy, and has contributed to groundbreaking research on dialysis/pharmaceutical medications and nutrition. Dr. Berkson consults internationally, focusing on medical nutrition for breast cancer, inflammatory bowel disease, renal problems, and complex health issues. Dr. B's Links: Email - admin@drlindseyberkson.com Webpage - www.drlindseyberkson.com Memberships - www.drlindseyberkson.com/membership Agile Thinking Substack - https://drlindseyberkson.substack.com/ Biotics Products - https://drlindseyberkson.com/bioticsproducts/ Hormones: Vilified to Vindicated (Course) - https://drlindseyberkson.com/v2v/ Oxytocin Medicine - https://drlindseyberkson.com/oxytocinmedicine/ **Get $100 off Dr. Berkson's Everything Breast Cancer and/or Everything Hormones Courses by using the code: PC100TARA https://drlindseyberkson.com/everythingbreastcancer/ https://drlindseyberkson.com/everything-breast-cancer-nonprofessional/ https://drlindseyberkson.com/everythinghormones/ Estradiol vs. Bi-Est Debate, watch here: https://www.youtube.com/watch?v=u-p82VW1weA&t=2508s Watch Tara's Instagram Live with Dr. Berkson here: https://www.instagram.com/reel/DN6ieQRE0PI/   Fix Your Gut Masterclass Stop Blaming the Food! The Real Reason You've Still Got Bloating and Pooping Problems and How to Fix Your Gut for Good. In this free, live masterclass Tara will walk you through the real reason your gut symptoms keep coming back, no matter what you've tried, and what actually needs to happen to fix them properly, at the root, for good. [Save your spot HERE]  

Does estrogen really cause breast cancer? It's one of the biggest fears women have when considering HRT, and in this conversation, Dr. Lindsey Berkson takes Tara back to where much of that fear began. They unpack the history of the Women's Health Initiative, how the original messaging around hormones shaped medical practice, and what later analyses of the research have shown. Dr. Berkson explains why she believes estrogen has been misunderstood, including the difference between estrogen's effects on different receptors and why "estrogen-positive" breast cancer does not necessarily mean estrogen caused the cancer. They also discuss research involving women with ER-positive breast cancer who received estrogen and what those studies reported. Dr. Berkson then shares her own breast cancer story and why it ultimately led her to spend decades researching hormones. This is a fascinating conversation about how medical messaging evolves, why women need to understand the details behind the studies, and why Tara believes these are conversations women deserve to have. In Part 1:  The history of the Women's Health Initiative and why it was created What the early research was actually showing about estrogen and breast cancer The controversial press release that changed the conversation around HRT What 20 years of reanalysis of the Women's Health Initiative revealed Oral vs topical vs vaginal estrogen: why delivery method matters Tara's experience with vaginal progesterone and sleep/anxiety The controversy surrounding oral progesterone The debate around estriol What "estrogen-positive" breast cancer actually means The theory behind estrogen and progesterone fueling breast tumors   Dr. Lindsey Berkson Lindsey Berkson, MA, DC, CNS, DACBN was a Distinguished Hormone Scholar at the Center for Bioenvironmental Research (CBR: Tulane/Xavier Universities). She is a leading figure in integrative medicine, renowned for her expertise in hormones, nutrition, digestion, and environmental science. With a background as a clinician, professor, bestselling author, and radio show host, she brings a wealth of experience to her work. At the CBR, she collaborated with pioneers in estrogen and sex-steroid receptor research. Dr. Berkson is also a respected educator, teaching MDs and pharmacists in advanced certification courses. She has developed innovative nutraceuticals, holds patents in bioidentical hormone therapy, and has contributed to groundbreaking research on dialysis/pharmaceutical medications and nutrition. Dr. Berkson consults internationally, focusing on medical nutrition for breast cancer, inflammatory bowel disease, renal problems, and complex health issues. Dr. B's Links: Email - admin@drlindseyberkson.com Webpage - www.drlindseyberkson.com Memberships - www.drlindseyberkson.com/membership Agile Thinking Substack - https://drlindseyberkson.substack.com/ Biotics Products - https://drlindseyberkson.com/bioticsproducts/ Hormones: Vilified to Vindicated (Course) - https://drlindseyberkson.com/v2v/ Oxytocin Medicine - https://drlindseyberkson.com/oxytocinmedicine/ **Get $100 off Dr. Berkson's Everything Breast Cancer and/or Everything Hormones Courses by using the code: PC100TARA https://drlindseyberkson.com/everythingbreastcancer/ https://drlindseyberkson.com/everything-breast-cancer-nonprofessional/ https://drlindseyberkson.com/everythinghormones/ Estradiol vs. Bi-Est Debate, watch here: https://www.youtube.com/watch?v=u-p82VW1weA&t=2508s Watch Tara's Instagram Live with Dr. Berkson here: https://www.instagram.com/reel/DN6ieQRE0PI/   Fix Your Gut Masterclass Stop Blaming the Food! The Real Reason You've Still Got Bloating and Pooping Problems and How to Fix Your Gut for Good. In this free, live masterclass Tara will walk you through the real reason your gut symptoms keep coming back, no matter what you've tried, and what actually needs to happen to fix them properly, at the root, for good. [Save your spot HERE]  

Join Dr. Clancy  and his guests, Drs. Ganesan and Mangala, as they discuss what is known about the microbiome, its relation to disease and how we can promote a healthy microbiome. Episode Transcript CE Credit Available Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Sukirth Ganesan, DDS, PhD, MPH Centennial Research Associate Professor Director of the Advanced Education Program in Periodontics University of Iowa College of Denistry and Dental Clinics Ashutosh Mangalam, PhD Professor of Pathology Interdisciplinary Graduate Program in Molecular Medicine University of Iowa Carver College of Medicine Financial Disclosures:  Dr. Gerard Clancy, his guests, and Rounding@IOWA planning committee members have disclosed no relevant financial relationships. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 1.00 ANCC contact hour. Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.) References/Resources:  Shahi SK, Ghimire S, Jensen SN, Lehman PC, Rux AG, Sinha S, Borcherding N, Tanas MR, Gibson-Corley KN, Ganesan SM, Karandikar NJ, Mangalam AK. IL-17A deficiency in HLA-DR3 transgenic mice enriches beneficial Prevotella species in gut to promote Tregs and reduce CNS autoimmunity. Microbiome. 2026 Jun 29;14(1):176. doi: 10.1186/s40168-026-02394-w. PMID: 42374500 Lehman PC, Ghimire S, Price JD, Ramer-Tait AE, Mangalam AK. (2023) Diet-microbiome-immune interplay in multiple sclerosis: Understanding the impact of phytoestrogen metabolizing gut bacteria. Eur J Immunol. Nov; 53(11):e2250236. DOI: 10.1002/eji.202250236. PMID: 37673213. Mendoza-Leon MJ, Mangalam AK, Regaldiz A, Gonzalez-Madrid E, Rangel-Ramirez MA, Alvarez-Mardonez OA, Vallejos OP, Mendez C, Bueno SM, Melo-Gonzalez F, Duarte Y, Opazo MC, Kalergis AM, Riedel CA. (2023) Gut microbiota short-chain fatty acids and their impact on the host thyroid function and diseases. Front Endocrinol (Lausanne). Jun 30; 14:1192216. DOI: 10.3389/fendo.2023.119226. PMID: 37455925. PMCID: PMC10349397.

Broadcast from KSQD, Santa Cruz on 8-06-2026: >ul> An emailer with persistent nine-month nerve damage in her right leg after a hysterectomy asks whether peptides could help. Dr. Dawn attributes the injury to lithotomy positioning during surgery, then reviews the main nerve-regeneration candidates in the FDA peptide review pipeline: BPC-157 (Body Protection Compound, strong rat data on sciatic nerve recovery with thicker myelin sheaths), intracellular sigma peptide (targets glial scar CSPGs blocking CNS regrowth), C3 peptide 156-181, GHK-Cu (copper peptide, upregulates nerve growth factor and neurotrophin-3), self-assembling hydrogel scaffolds for bridging nerve gaps, ARA-290/cibinetide (an erythropoietin fragment with early small fiber neuropathy trial data), and Semax (used internationally for stroke rehab). She adds standard functional-medicine adjuncts: alpha-lipoic acid, methylated B12, and methylfolate at high doses for six months. An emailer asks about safe features when buying an infrared sauna. Dr. Dawn covers three concerns: EMF exposure (look for shielded/grounded heaters testing under 1 milligauss at seat level, avoid unshielded Wi-Fi and Bluetooth panels); VOC off-gassing (avoid plywood, particle board, and MDF because of formaldehyde and benzene release, and avoid Western red cedar and pine because of high terpene emissions and instead choose poplar, basswood, or eucalyptus); and avoid built-in oxygen ionizers, which produce ozone as a coronal-discharge byproduct that irritates airways and generates secondary oxygenated VOCs. Dr. Dawn covers the surprisingly long list of medications that raise estrogen in middle-aged men—including nearly all antidepressants and antiepileptics, statins, NSAIDs (specifically naproxen and indomethacin but not ibuprofen), most blood pressure medications, PPIs, H2 blockers, Parkinson's drugs, antihistamines, and muscle relaxants. She recommends annual monitoring of the estrogen-to-testosterone ratio and offers rebalancing options: topical chrysin (blocks aromatization), indole-3-carbinol, calcium D-glucarate (blocks enterohepatic estrogen recirculation), soy (competitive receptor inhibition), and grape skin extract. The first mRNA-based flu vaccine was approved this week for adults 50 and over. Beyond the 27% improvement in seasonal efficacy over conventional shots, the strategic advantage is manufacturing speed. This will be critical when or if bird flu mutates to respiratory human transmission. Since mRNA vaccine can be reprogrammed from a new viral sequence in weeks versus the three-to-four-month growth cycle for conventional flu vaccines, rapid response can save lives. But mRNA vaccine side effects include more injection-site pain and fatigue - more like a tetanus shot than a traditional flu shot.. A Spanish prospective study of chemicals affected puberty in the young studied 500 girls followed from ages 7-10 and again at 14-16 used urine chemical measurements as objective exposure markers rather than food diaries. Ethylenethiourea, a metabolite of dithiocarbamate fungicides used heavily on strawberriess,was associated with earlier menarche, while a chlorpyrifos metabolite was associated with delayed menarche. this latter effect was more pronounced in overweight girls whose fat tissue concentrated the compound. Dr. Dawn recommends organic strawberries and keeping children away from fumigated fields. University of Pennsylvania School of Dental Medicine researchers developed a chewing gum from lablab beans containing the natural antiviral protein FRIL, which reduced oral HPV by up to 93% in samples from head and neck squamous cell carcinoma patients. The gum also suppressed Fusobacterium nucleatum and Porphyromonas gingivalis, oral bacteria that promote cancer recurrence. Michigan State University's Hamburger lab studying delphinium (larkspur) alkaloids joined forces with Tomáš Pluskal's Czech Academy of Sciences lab studying wolfsbane (monkshood) after meeting at a Barcelona conference. Together they mapped the biosynthetic assembly line for aconite—an alkaloid with valuable applications against malaria, pain, cancer, and agricultural pests but impossibly slow to extract from source plants—and cloned the pathway into tobacco, which grows aggressively and produces large quantities of the compound. An emailer named in the message asks about an incidentally-discovered enlarged aorta on CT. Dr. Dawn notes it officially becomes an aneurysm at 4 cm (annual monitoring) or 5 cm (six-month monitoring), with smoking cessation critical since tobacco directly weakens the aortic wall. She describes the "zipper of fire" back pain of dissection versus catastrophic rupture, and notes Medicare covers a one-time screening ultrasound for ever-smokers over 65.

In this episode, Jennifer Venator, MSN, RN, CNS, CNOR, CRNFA, Executive Director, Surgical Services, Providence St. Jude Medical Center in Fullerton CA, shares how trusted, real-time data is improving surgical access, operational efficiency, and collaboration across care teams. She also discusses how automation and emerging AI capabilities can streamline perioperative workflows, reduce administrative burden, and help clinicians stay focused on patient care.

Are you tired of conflicting nutrition advice on social media? One day potatoes are "bad," the next day avocados are the problem. In this episode, we cut through the noise and explain why healthy eating doesn't have to be so complicated, and why intuitive eating makes so much sense. Why extreme diet trends are doing more harm than good The truth about intuitive eating and whole foods How social media influencers create confusion around nutrition Why sugar cravings and food addictions are more complex than willpower Simple strategies to build healthier eating habits that actually last Why meeting people where they are leads to sustainable lifestyle change How cooking at home and shopping for real food can transform your health Dr. Terri is joined by Elizabeth DiMeo, MS, CNS, LDN, Director of Education and Clinical Nutritionist at EVEXIAS Health Solutions. A Certified Nutrition Specialist and Licensed Dietitian Nutritionist with 25 years in clinical practice — and a former chef — Elizabeth has spent her career translating nutrition science for both practitioners and patients. She's also the person who will tell you, without apology, that a potato roasted in olive oil with chives and grass-fed butter is not the enemy. This conversation started as a rant about Instagram and turned into something more useful: an honest look at what "intuitive eating" actually means, why restriction culture has made people afraid of real food, and how clinicians should actually counsel someone who wants to change — not with a list of things to quit, but with things to add. Along the way: the three-day food log that reveals everything, the patient drinking six Big Gulps a day who became migraine-free, what cravings are really signaling, and how reference ranges quietly normalized a metabolic epidemic. If you're overwhelmed by conflicting food advice, tired of being told everything you enjoy is killing you, or you're a clinician trying to help patients who won't follow a perfect plan — this one's for you. What you'll discover in this episode: [00:57] / 00;07;22 — The Instagram post that set this whole conversation off, and what it gets backwards about fat [05:38] / 00;12;03 — What intuitive eating actually means — and how it got confused with hedonistic eating [09:47] / 00;16;12 — Paleolithic man didn't just eat meat: why the carnivore framing misreads history [14:26] / 00;20;51 — Meeting people where they are: nutrition advice that works on a real budget [16:14] / 00;22;39 — The three-day food log, what patterns it reveals, and why shame has no place in it [20:19] / 00;26;44 — Cheese, rennet, and the serving size almost nobody is actually eating [23:56] / 00;30;21 — Add before you subtract: the counseling approach that makes change stick [24:39] / 00;31;04 — Six Big Gulps a day, chronic migraines, and a year-long taper that worked [29:05] / 00;35;30 — Cravings as nutrient deficiency: pica, ice chewing, and what salt is really telling you [31:11] / 00;37;36 — How shifting lab reference ranges quietly normalized fatty liver and elevated fasting insulin [41:54] / 00;48;19 — "If you can't pick it, pull it, or kill it" — the simplest food rule in the episode [48:03] / 00;54;28 — Farmers markets, teaching kids to cook, and making whole food a family habit Food was never supposed to be this complicated. The Dr. Terri Show is presented by EVEXIAS Health Solutions. EVEXIAS Health Solutions is an emerging leader in integrative medicine on a mission to positively impact people's lives through the transformation of health care. EVEXIAS educates and trains practitioners on new, innovative, integrative therapies that support a preventative care model that drives vitality as you age. Learn more and find a provider near you at https://www.evexias.com Connect with Dr. Terri:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By combining their resources, the new entity is expected to enhance its capabilities in neurological disorders with a robust portfolio of approved drugs. This merger allows the companies to leverage economies of scale, optimize research and development, and expand their market presence, offering promising prospects for advancements in treating CNS-related conditions. In regulatory news, Novartis has secured FDA approval for an expanded indication of Pluvicto (lutetium vipivotide tetraxetan), a radioligand therapy originally approved for PSMA-positive metastatic castration-resistant prostate cancer. This therapy can now be used for metastatic hormone-sensitive prostate cancer, marking a significant step forward in prostate cancer treatment. By targeting prostate-specific membrane antigen (PSMA) with precision, Pluvicto offers the potential for improved patient outcomes and highlights the growing role of radioligand therapies in oncology. Globally, Pharmamar's Zepzelca (lurbinectedin) has been approved in Canada, Qatar, and South Korea as a first-line maintenance therapy for extensive-stage small cell lung cancer. This approval signifies a potential shift in how aggressive cancer types are treated, particularly when combined with PD-L1 inhibitors, opening new avenues for effective combination therapies. Industry partnerships continue to drive innovation, as seen with Fujifilm and Taiho Pharmaceutical's collaboration to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the Aralinq platform. With ADCs becoming increasingly pivotal in targeted cancer therapies due to their precision in delivering cytotoxic drugs to tumor cells, advancements in manufacturing could significantly enhance production capabilities and therapeutic efficacy. Financial dynamics within the industry remain robust. AbbVie has raised its 2026 revenue forecast to $67.6 billion, citing strong performances from its immunology drugs Skyrizi and Rinvoq. These therapies have shown substantial success in treating autoimmune conditions, reflecting their impact on AbbVie's financial health and reinforcing confidence in their commercial viability. On the clinical trial front, Ratio Therapeutics has successfully closed a $70 million Series C funding round to support its radiotherapeutics pipeline and initiate the ATLAS trial. This infusion of funds underscores the continued interest and investment in radiopharmaceuticals with promising applications in oncology. The landscape of mergers and acquisitions remains active as AstraZeneca and Bristol Myers Squibb reportedly engage in early-stage merger discussions. Such a merger could create an oncology giant valued at approximately $400 billion, potentially reshaping competitive dynamics and accelerating innovation across therapeutic areas. Regulatory changes are also underway with HRSA advancing a revised 340B rebate model pilot program despite hospital opposition. The implications for healthcare providers are significant as this could affect operational efficiencies and financial strategies within participating entities. Overall, these developments reflect ongoing trends toward industry consolidation and strategic partnerships that foster innovation in drug manufacturing technologies. Regulatory approvals continue to advance precision medicine through targeted therapies, showcasing the sector's dynamic nature as it addresses unmet medical needs while navigating complex regulatory environments. Meanwhile, Sandoz's settlement of nearly $500 million for antitrust claims in the U.S. highlights ongoing scrutiny of industry competition practices. This settlement signals potential shifts in market dynamics as companies seek to resolve legal challenges while maintaining operational integrity. Cybersecurity has emerged as a critical concern following Amgen's reported breach compromising sensitive patient data. This incident amplifies the need for enhanced data protection measures to safeguard information integral to patient trust and competitive integrity. In leadership news, BioNTech has appointed Guido Oelkers as CEO amid its continued innovation in mRNA technology post-COVID-19. This strategic move underscores BioNTech's commitment to leadership capable of navigating advances in mRNA therapeutics. Lastly, Novo Nordisk faced setbacks with its investigational therapy ziltivekimab failing a phase 3 trial targeting inflammatory pathways for cardiovascular outcomes. Despite such challenges, these high-stakes trials highlight both risks and opportunities inherent in pharmaceutical innovation. As we reflect on these stories, it's clear that scientific advancements, regulatory developments, and strategic business moves continue to shape the trajectory of the pharmaceutical and biotech sectors. These efforts promise significant implications for future drug development and patient care as companies strive to harness breakthroughs while adapting to evolving industry landscapes.Support the show

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today.Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them.Topics discussed:Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06)Bilal's personal story and the events that guided his commitment to Parkinson's research and entrepreneurship (04:03)How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05)The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson's disease mechanisms (11:31)The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38)Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26)The current status of Azure's preclinical and manufacturing development, and their plans for clinical translation (14:31)Why previous therapies for Parkinson's have fallen short, and how cell therapy might sidestep these limitations (15:57)The potential and challenges of using cell therapy for other brain diseases like Alzheimer's (18:26)Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures.If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung WooEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale BernatchezEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeConnect with Bilal Fares:LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: info@azurecell.coSupport the show

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

In collaboration with ROESCG, we introduce a new series, Cancer Careers! Today we're joined by Dr. Justin Oh, a Radiation Oncologist at BC Cancer in Vancouver who specializes in CNS and pediatric cancers, and has a strong research interest in population-based outcomes.

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas LewGuest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.In this episode, we break down the biggest lymphoma and CLL data from ASCO and EHA 2026 (Chicago and Stockholm), covering mantle cell lymphoma genomics, bispecific antibodies in DLBCL and follicular lymphoma, a practice-changing (or not) CNS prophylaxis study, transplant-eligible relapsed DLBCL, fixed-duration BTK/BCL2 combinations in CLL, and the first in vivo CAR T data in lymphoma.1. TRIANGLE: TP53-Mutated MCL Molecular Subgroup AnalysisMolecular subgroup data from the practice-shaping TRIANGLE trial presented by Dr. Marta Grau.Discussion: Where TP53-mutated MCL stands today, and whether ibrutinib-containing regimens are changing the natural history of this historically dismal subgroup.2. EPCORE DLBCL-1: Epcoritamab vs. Chemotherapy in R/R DLBCLRandomized phase 3 trial (n=483) of bispecific antibody epcoritamab vs. investigator's choice chemotherapy (72% R-GemOx, 28% BR) in second-line-or-later, transplant-ineligible R/R DLBCL, presented by Prof. Chris Fox.Discussion: A PFS benefit without an OS signal, set against a meaningfully higher infection-related mortality — what this means for patient selection and infection mitigation strategies.3. CNS Prophylaxis in Ultra-High-Risk DLBCL: Does HD-MTX Help?Pooled analysis of two large multicenter retrospective cohorts (n=1,923 ultra-high-risk patients — CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), presented by Dr. Matt Wilson (Glasgow) and simultaneously published in JCO. Discussion: Whether these data close the door on routine HD-MTX in ultra-high-risk DLBCL, and if any subgroup still warrants prophylaxis.4. Pola-R-ICE: A Negative Trial in Transplant-Eligible R/R DLBCLRandomized phase 3 study (4 European cooperative groups; n=294) of polatuzumab vedotin added to R-ICE in transplant-eligible R/R DLBCL, with ASCT/alloSCT/CAR-T permitted as consolidation.Discussion: Why this trial missed, and what it tells us about the ceiling of intensive salvage chemo-immunotherapy platforms in the CAR-T era.5. BRUIN-CLL-322: Fixed-Duration Pirtobrutinib + Venetoclax-Rituximab in R/R CLLRandomized phase 3 trial (n=639) of fixed-duration pirtobrutinib (non-covalent BTKi) plus venetoclax-rituximab (PVR) vs. venetoclax-rituximab (VR, the MURANO-based control) in second-line-or-later R/R CLL.6. SOUNDTRACK-F1: Surovatamig (CD19 Bispecific) Safety Run-In in Untreated Follicular LymphomaSafety run-in from a randomized trial (surovatamig vs. chemoimmunotherapy) in untreated FL meeting GELF criteria, presented by Prof. Chan Cheah — building on EPCORE-FL-1 data presented at ASH.Discussion: How this CD19-directed bispecific compares to CD20-targeting agents in frontline FL.7. LB2501: First In Vivo CAR T Data in B-Cell LymphomaLate-breaking data from Dr. Lei Fan and Legend Biotech on LB2501, an in vivo CD19/CD20 dual-targeted CAR T therapy — a third-generation, self-inactivating, replication-incompetent lentiviral vector that generates CAR T cells directly in vivo, without lymphodepletion. Builds on the in vivo CAR T myeloma data first presented at ASH and updated at EHA.Discussion: What these very early but striking data suggest about the feasibility of in vivo CAR T generation in lymphoma, and how it might reshape access to cellular therapy.BloodCancerTalks is co-hosted by Rajshekhar Chakraborty,  Ashwin Kishtagari and Eddie Cliff. Subscribe wherever you get your podcasts. 

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of diffuse large B-cell lymphoma (DLBCL) for 2026, updating their prior coverage to reflect several recent practice changes.The discussion began with clinical presentation, emphasizing the classic B symptoms—weight loss, night sweats, fatigue, and fever—alongside painless, rapidly enlarging lymphadenopathy. They noted that approximately 30% to 40% of cases present with extranodal involvement (gastrointestinal, central nervous system [CNS], or thyroid) and stressed that an excisional biopsy is required, as fine-needle aspiration cannot preserve the architecture needed for histologic grading.Turning to classification, Drs Armstrong and Tawagi reviewed germinal center vs non-germinal center origin, with non-germinal center disease carrying a worse prognosis. They characterized double-hit lymphoma, triple-hit lymphoma, and double-expressor lymphoma, the last conferring an intermediate prognosis.Regarding workup, they recommended full-body PET scans, laboratory evaluation for tumor lysis syndrome, hepatitis B testing before anti-CD20 therapy, baseline echocardiography before anthracyclines, and lumbar puncture with intrathecal methotrexate in patients at high risk for CNS relapse. They also reviewed updated staging systems.For treatment, they explained that limited-stage disease is now stratified by the stage-modified International Prognostic Index (IPI), guiding abbreviated vs full R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone). In advanced disease, 6 cycles of R-CHOP remains standard, with polatuzumab vedotin-piiq (Polivy) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) now a category 1 regimen for patients with an IPI of 2 or greater. They also addressed dose-adjusted regimens for double-hit disease, CAR T-cell therapy, and bispecific antibodies in the relapsed/refractory setting, as well as surveillance recommendations, cautioning against routine PET imaging.

In this episode the guys break down six ways to build bulletproof joints — proper strength training, unilateral training, static stretching post-workout, mobility drills, hydration with high protein diet, and consistent sleep. They cover why joints actually strengthen rather than wear down with proper use, why MAPS Symmetry alone solves most chronic pain issues without targeted correctional exercise, and why CNS tightening after workouts causes the low back pain people feel hours later at night. They also get into a new study showing probiotics plus protein powder outperforms protein powder alone for strength gains, creatine reducing anxiety in 95% of postmenopausal women, Sal's return to jiu jitsu and the cardio humbling he's getting from a one-year practitioner, Doug's 4th of July river rafting trip on the American River, Sal's son's emotional breakdown watching the USA World Cup loss, and Adam going deep on the Vuori wetsuit situation. Then they answer questions from Instagram. MAPS Upper Lower: https://mapsupperlower.com Code: LAUNCH for 40% off. Male and female programs, workout videos, exercise demos and live coaching with Cole. SPONSORS LMNT (electrolytes): https://drinklmnt.com/MindPump Free 8-count sample pack with any purchase. No code needed. No-questions-asked refunds on all orders. Discussed on air — Sal swears by it before sauna and the study on electrolytes and migraines. Vuori: https://vuoriclothing.com/mindpump 20% off first order, no code needed, automatically applied. Doug wore their wetsuit for the first time on the rafting trip. Caldera Lab (Hydro Layer skincare): https://calderalab.com/mindpump Code: MINDPUMP20 for 20% off first order. Visibly reduces lines and wrinkles, firms skin, all-day hydration. 90%+ of users report visible improvement quickly. LINKS Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia SPOTIFY TIMESTAMPS 0:00 - Intro 0:13 - How to build bulletproof joints — can joints actually get stronger? 3:20 - Tip #1: Proper strength training — data shows cartilage gets thicker with proper training 9:12 - Tip #2: Unilateral training — why MAPS Symmetry alone corrects most chronic pain 13:08 - Why the weaker side has to dictate the workout and why this is psychologically hard 18:28 - Tip #3: Static stretching post-workout — why your CNS stays tight after training and causes late-night pain 23:01 - Tip #4: Mobility drills — owning ranges of motion through active movement 26:26 - Tip #5: Hydration and high protein — lubrication, connective tissue and why collagen hype has merit 22:00 - Tip #6: Sleep — the number one recovery and adaptation tool 23:01 - LMNT deep dive — the downstream benefits, electrolytes and migraines study 27:06 - Endurance study: 120g carbs per hour means cyclists lose less than a third of their power 28:20 - Sal's jiu jitsu update — getting humbled by a one-year practitioner on cardio efficiency 34:14 - Doug's 4th of July American River rafting trip — wetsuit success and guide goes overboard 43:00 - Sal's son breaks down crying watching USA lose the World Cup 51:07 - Probiotics plus protein beats protein alone for strength gains 52:12 - Creatine reduces anxiety in 95% of postmenopausal women 58:22 - Q&A: One muscle group once per week vs. twice per week for natural lifters 1:00:27 - Q&A: How can you lose muscle and gain fat while in a calorie deficit? 1:00:27 - Q&A: Best home exercises to improve ankle mobility 1:01:39 - Q&A: What other neglected muscles and exercises should people be training?

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics: ·      Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00) ·      Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of first-line treatment and maintenance approaches for HER2-positive mBC (5:26) ·      Efficacy and safety findings from the Phase III DESTINY-Breast09 trial comparing trastuzumab deruxtecan with or without pertuzumab to taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC (14:56) ·      Predictors of long-term benefit from first-line treatment with HER2-targeted agents; contribution of pertuzumab to the efficacy of first-line HER2-targeted combination regimens (22:57) ·      Control of brain metastases and CNS disease with first-line HER2-targeted regimens (26:31) CME information and select publications

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Julie Wendt, MS, LDN, CNS, adjunct instructor, Integrative Medicine Programs, Department of Clinical Research and Leadership, GW School of Medicine & Health Sciences, recently gave a talk on staying hydrated as the temps and humidity rise to summertime highs. As Licensed Dietician Nutritionist (LDN), Julie is a highly trained food and nutrition expert. LDNs and Registered Dietitian Nutritionists (RDN) are the only credentialed professionals legally qualified to provide medical nutrition therapy, assess nutritional needs, and build specialized meal plans for specific medical conditions. She is a LDN is Maryland, a Licensed Nutritionist in D.C., and a Certified Nutrition Specialist (CNS). Julie earned a Masters of Science in Integrative Health and Nutrition from Maryland University of Integrative Health. ◘ Related Links Julie Wendt Nutrition www.juliewendtnutrition.com Julie's Hydration Checklist https://bit.ly/4w0xx00 ◘ Transcript bit.ly/3JoA2mz ◘ Disclaimer: The content and information shared in GW Integrative Medicine is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in GW Integrative Medicine represent the opinions of the host(s) and their guest(s). For medical advice, diagnosis, and/or treatment, please consult a medical professional.

We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic innovation could come from. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

It was an absolute honor to meet today's guest, and I was honestly a bit starstruck! She is rooted equally in both the science of food and intuitive eating. We dove into the phytochemistry of nutrients, and most importantly, discussed the fundamental principles for healthy eating. Dr. Deanna Minich, PhD, CNS, IFMCP is a pioneering nutrition scientist and thought leader with over 25 years of experience bridging science, spirituality, and art to redefine holistic health. Internationally recognized for her work on color-coded nutrition (“eating the rainbow”), detoxification, and hormone health, Dr. Minich brings a multidimensional lens to wellness that is both grounded in research and infused with a soulful approach. For over a decade, she worked closely with the “Father of Functional Medicine,” Dr. Jeffrey Bland on R&D and functional medicine education with the Institute for Functional Medicine and assisting with the start-up of the Personalized Lifestyle Medicine Institute (PLMI) and now on the Board for PLMI. In 2025, she was awarded the Linus & Ava Helen Pauling Award by the Institute for Functional Medicine, one of the highest honors in the field, for her groundbreaking contributions to science-backed integrative health. As the Chief Science Officer at Symphony Natural Health, Dr. Minich leads the Science-Medical Team's innovation in endocrine, metabolic, and circadian health, developing evidence-based approaches that empower people to reclaim vitality through rhythm, root-cause healing, and renewal. A passionate educator and communicator, she develops transformative curricula and continuing education for health professionals, while also creating accessible, inspiring resources for the general public. Her work meets people where they are, whether they're practitioners seeking clinical precision or individuals seeking a deeper connection to their body's wisdom. Connect with Dr. Deanna via: Email: info@foodandspirit.com Website: Dr. Deanna Minich FB: Deanna Minich, PhD IG: @deannaminich YT: @foodandspirit Linked In: Deanna Minich, PhD, MS, FACN, CNS, IFMCP Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.

Broadcast from KSQD, Santa Cruz on 6-25-2026: Dr. Dawn devotes the show's opening to ivermectin for COVID. She walks through critical thinking principles—considering the source, cross-verification, and recognizing self-interested claims—before reviewing the evidence. The most-cited 2021 Bulgarian study of 300 people showing 77% reduction lacked accessible methods, and larger trials capable of detecting even small benefits failed to confirm efficacy. On safety, the standard 12mg parasitic dose every few weeks is well-tolerated due to the blood-brain barrier and efflux pumps that keep ivermectin out of the brain, but daily long-term dosing has caused encephalopathy, liver and kidney damage, and birth defects. Critical drug interactions—macrolide antibiotics, verapamil, proton pump inhibitors, and beta blockers—disable the efflux mechanism, and high-fat meals increase absorption 2.5-fold. Dr. Dawn shares two inflammation formulas calculable from any CBC. The Systemic Inflammatory Index (neutrophils × platelets ÷ lymphocytes) flags runaway inflammation: 200-500 is good, above 900 warrants investigation and correlates with worse stroke outcomes and rising tumor burden. The SIRI (neutrophils x monocytes ÷ lymphocytes) detects chronic tissue inflammation and early innate immune activation: below 500 is good, above 1500 indicates trouble and correlates with cardiovascular mortality and arterial plaque from M1 macrophage activity. Dr. Dawn shares two takeaways from the Institute for Functional Medicine annual conference: in patients at high cardiovascular risk by cholesterol, each gram daily of combined EPA/DHA produces a 9% risk reduction, with bruising as the dose-limit signal. Additionally, a 15-minute walk within 30 minutes of a meal nearly eliminates postprandial inflammation. An emailer asks whether an endocrinologist's claim that vitamin D leaches calcium from bones is true. Dr. Dawn confirms that very high vitamin D (above 150 nanograms, with concern starting above 90) elevates 1,25-vitamin D, which stimulates osteoclast formation and increases C-telopeptide markers of bone breakdown. A crowdsourced question asks how histamines work in women. Dr. Dawn explains histamine functions as a CNS neurotransmitter promoting alertness, wakefulness, and pain perception (deficient in narcolepsy), and as a GI signal driving acid secretion, motility, and visceral sensation. Gut bacteria can convert histidine to histamine, and fish left to spoil can trigger anaphylactic-like reactions from accumulated bacterial histamine. She notes stomach acid treatments Tagamet and Zantac are H2 blockers rather than the more familiar H1 antihistamines, and confirms histamine correlates with hormones but not particularly with minerals. A crowdsourced question on B vitamins for women in their mid-twenties prompts Dr. Dawn to recommend prenatal vitamins for those who might become pregnant, and B100 complex with calcium taken with a little apple cider vinegar for those on restricted diets or eating mostly fast food. Another question asks about chest versus belly breathing. Dr. Dawn explains babies demonstrate proper diaphragmatic breathing (belly protrudes on inhalation) while accessory muscle use signals fight-or-flight—or pneumonia in a non-crying infant. Chest breathing raises adrenaline; belly breathing calms it in adults. How do I stop compulsive scratching? Dr. Dawn explains neurodermatitis has its own ICD-10 code alongside compulsive nail-biting and hair-pulling, and it is diagnosed by sparing of unreachable areas like the mid-back between shoulder blades. Treatment includes nail clipping, lubricants, covering scabbed areas, and Prozac—which uniquely among antidepressants has a secondary indication for neurodermatitis. Zurich researchers combined immature human nerve cells with magnetic nanoparticles to create 6-micrometer NPC bots that can be magnetically positioned at spinal cord injury sites and then triggered by pulsatile magnetic stimulation to mature into nerve tissue. Mice with severed spinal cords regained movement and brain-muscle electrical signals by day 34 after daily 30-minute treatments. A study of 15,000 people with myalgic encephalomyelitis/chronic fatigue syndrome identified eight genetic regions distinguishing them from controls. Two relate to immune response to infection—consistent with the post-infectious onset many sufferers describe, including roughly half of long COVID patients—and others link to the nervous system and chronic pain. Dr. Dawn frames ME-CFS as an immune system stuck in the "on" position, unable to brake against an enemy that is long gone. An emailer asks about prostate biopsy approaches. Dr. Dawn explains the new transperineal biopsy (through skin between scrotum and anus) reduces post-biopsy infection from 1.5% to near zero and eliminates prophylactic antibiotics, though it requires more anesthesia and time. Cancer detection rates match the transrectal approach when both use MRI targeting, and she expects the transperineal approach to become standard.

Send us Fan MailStarting January 1, 2027 every antepartum visit becomes its own billable E/M charge. The global OB code goes away. The seventeen deleted codes include 59400, 59510, 59425, and 59426. And the way most prenatal notes are written today supports a 99212 at best, even when the visit was genuinely a 99214. Dr. Heather Signorelli and Maria Reynoso, Director of RCM at NatRevMD, walk through what changes, what the notes have to say, and the three actions every OB practice should take this week. What changes January 1, 2027: Antepartum-only codes (59425, 59426) and global OB codes (59400, 59510) are deleted. Every prenatal visit is now a standard E/M visit with modifier TH. New patient 99202–99205. Established patient 99211–99215. What the notes actually look like today: Notes have been written for speed because the global model did not reward note detail. A typical 16-week prenatal note (BP, fundal height, FHTs, “patient doing well, return in 4 weeks”) supports a 99212. The provider did much more during that visit. None of it is in the note. Under 2027, that gap is real revenue. What a 99214 note has to say: ACOG's position: pregnancy is a chronic illness with exacerbation and progression for E/M purposes. The complexity is built in. The note has to reflect it. For a 99214, document the ongoing management of the pregnancy as a condition, the data reviewed with your interpretation, and moderate risk decisions like prescription management or monitoring a condition that could escalate. “Anatomy scan reviewed, normal” is a 99212. “Anatomy scan reviewed, normal four-chamber heart, no CNS abnormality, EFW consistent with dates, AFI normal, counseled patient” is a 99214. High-risk patients finally pay for the complexity of their care: Under the global model the complex patient and the low-risk patient paid the same. The new model fixes that two ways. Complex visits code at a higher level (99214 / 99215). And more frequent visits equal more claims. For 99215 the note needs the specific complicating diagnosis named, data reviewed with interpretation, the management decision and the reason behind it, and specialist coordination if applicable. Same-day procedures and modifier 25: Antepartum procedures (NSTs, ultrasounds, amniocentesis, CVS) still bill separately. The E/M visit on the same day is now also billable with modifier 25. The note must independently support the E/M, not just the procedure. Three actions this week: Audit twenty random prenatal notes against the 2021 E/M guidelines to set your baseline Rebuild EHR templates to prompt for MDM elements, not for speed Start documentation training in Q3, using providers' own notes side by side with the corrected version and the dollar difference Quick Reference Table:       Topic                                                                                    What to knowDeleted codes count                     -      17 codes deleted total Antepartum-only codes                  -       59425, 59426 — deleted Jan 1, 2027Global OB codes                                  -       59400, 59510 — deleted Jan 1, 2027 New patient E/M range                    -       99202–99205 + modifier TH Established patient E/M range    -       99211–99215 + modifier TH 99214 vs 99213                              -       ~$46 per visit at Medicare ratesModifier 25               -       On the E/M when a procedure is also billed same dayACOG test date         -September 1, 2026 — recommended start for test claimsRVU finalization       - CMS proposes July 2026, finalizes November 2026 RESOURCES BLOCK Save your seat: Live OB/GYN Global Codes Update Webinar (July 7, 2026, 4:00 PM ET) · eligibility.natrevmd.com/obgyn-global-updates-webinar Book a 1:1 with Dr. Signorelli · calendly.com/heather-natrevmd/ Practice Revenue Leak Scorecard · eligibility.natrevmd.com/nrm-revenue-scorecard-v3 Payment Posting Audit Checklist · eligibility.natrevmd.com/payment-posting-checklist RECOVER Diagnostic Quiz · natrevmd.com/quiz Series Part 1 (EP188): https://podcasts.apple.com/us/podcast/188-17-ob-codes-just-got-deleted-your-real-deadline/id1624182351?i=1000773393336Coming next: EP191 · Phase 2 labor management codes (the codes that have never existed in CPT before) 

Could Hashimoto's be the missing root cause behind your thyroid symptoms?If you have been told your thyroid labs are “fine,” or you are taking thyroid medication but still feel exhausted, foggy, inflamed, or not like yourself, this conversation will help you understand what may be happening underneath the surface. Hashimoto's is not just a thyroid problem. It is an immune system condition that can keep attacking the thyroid when the deeper triggers are never addressed.Inna Topiler, CNS, MS, is a Certified Nutrition Specialist who has navigated her own Hashimoto's journey for over 25 years. She is the host of Thyroid Mystery Solved: Hashimoto's and Hypothyroidism Revealed, and the creator of Thyroid Love, a 26-nutrient supplement formulated specifically for thyroid autoimmunity.In this conversation with Dr. Shivani Gupta, Inna explains the immune confusion behind Hashimoto's, why thyroid medication alone does not calm the immune attack, and what it really takes to support thyroid health at the root.What You'll Learn in This Episode:Why levothyroxine supports the thyroid but does not address the immune attack causing the damage?How to ask for a real full thyroid panel, and why TPO and TG antibodies matterThe four root cause buckets behind immune confusion: food, infections, toxins, and stressWhy gluten can trigger an immune attack on the thyroid through molecular mimicryThe truth about iodine supplementation with Hashimoto's, and why it often makes things worseHow selenium and inositol support thyroid hormone balance and immune regulationWhy zinc deficiency can be generational and how high copper compounds the problemWhat a thyroid supplement designed for autoimmunity should and should not includeThe Inflammation Codehttps://www.amazon.com/dp/140199699X?tag=usalinktagdefault-20&th=1&psc=1&geniuslink=trueFusionary Formulas SupplementsUse code CODE15 for 15% off your first orderhttps://fusionaryformulas.com/?utm_source=Show+Notes&utm_medium=Show+notes+&utm_campaign=Podcast+promo&utm_id=The+Inflammation+Code+Podcast7-Day Inflammation Detox Challengehttps://www.7dayinflammationdetox.com/Work with Dr. Shivani / Free Discovery Callhttps://shivanigupta.com/

Many disease‑causing genes are too large to be packaged into standard AAV gene therapy vectors, leaving a long list of otherwise gene-therapy-ready conditions without viable treatments. SpliceBio is leveraging a protein splicing platform based on engineered split inteins to overcome the cargo limitations of AAV gene therapy vectors, enabling delivery of large genes to potentially treat a broad range of monogenic conditions. The company's lead program is a dual AAV gene replacement therapy to treat Stargardt disease, a rare inherited condition that causes progressive vision loss. Miquel Vila-Perello, CEO of SpliceBio, discusses the company's platform technology that enable to the delivery of large genes in AAV vectors, its work to date in Stargardt disease, and preclinical data across more than 20 large-gene targets supporting its platforms use in ophthalmology and CNS indications.

I sit down with nutrition scientist Dr. Luke Bucci to explore the powerful connection between blood flow, nitric oxide, mitochondrial health, and healthy aging. We discuss why circulation impacts nearly every function in the body, what causes energy levels to decline with age, and how nutrition, exercise, and targeted supplementation may help support long-term vitality. Dr. Bucci also explains the science behind nitric oxide, blood sugar regulation, and the role mitochondria play in keeping us energized and resilient throughout life.Dr. Luke Bucci, PhD, CNS, CCN is the Chief Scientific Officer of Juvenon and a biomedical scientist with more than 40 years of experience in nutrition, dietary supplements, and clinical laboratory science. He earned his PhD in Biomedical Sciences from the University of Texas Health Science Center at Houston and has helped develop numerous patented nutritional products used worldwide. A recognized authority in healthy aging, sports nutrition, omega-3s, probiotics, and dietary supplement science, Dr. Bucci has authored scientific books, taught university-level courses, and received multiple industry awards for his contributions to nutrition and health innovation.Links mentioned during this episode:Juvenon: https://juvenon.com/Free Initial Consultation with Dr. Megan: https://p.bttr.to/3a9lfYkLyons' Share Instagram: www.instagram.com/thelyonsshareJoin Megan's newsletter: www.thelyonsshare.org/newsletter

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Full Text of Readings The Solemnity of the Most Holy Body and Blood of Christ Lectionary: 167 The Saint of the day is Blessed Franz Jägerstätter Blessed Franz Jägerstätter, an Austrian farmer executed for refusing to fight for Nazi Germany, is pictured in an undated photo. (CNS photo)  Saint of the Day for June 7 (May 20, 1907 – August 9, 1943) Blessed Franz Jägerstätter's Story Called to fight for his country as a Nazi soldier, Franz Jägerstätter eventually refused, and this husband and father of three daughters—Rosalie, Marie and Aloisia—was executed because of it. Born in St. Radegund in Upper Austria, Franz Jägerstätter lost his father during World War I and was adopted after Heinrich Jaegerstaetter married Rosalia Huber. As a young man, he loved to ride his motorcycle and was the natural leader of a gang whose members were arrested in 1934 for brawling. For three years he worked in the mines in another city and then returned to St. Radegund, where he became a farmer, married Franziska and lived his faith with quiet but intense conviction. In 1938, he publicly opposed the German Anschluss–annexation–of Austria. The next year he was drafted into the Austrian army, trained for seven months and then received a deferment. In 1940, Franz was called up again but allowed to return home at the request of the town's mayor. He was in active service between October 1940 and April 1941, but was again deferred. His pastor, other priests, and the bishop of Linz urged him not to refuse to serve if drafted. In February 1943, Franz was called up again and reported to army officials in Enns, Austria. When he refused to take the oath of loyalty to Hitler, he was imprisoned in Linz. Later he volunteered to serve in the medical corps but was not assigned there. During Holy Week Blessed Franz Jägerstätter wrote to his wife: “Easter is coming and, if it should be God's will that we can never again in this world celebrate Easter together in our intimate family circle, we can still look ahead in the happy confidence that, when the eternal Easter morning dawns, no one in our family circle shall be missing—so we can then be permitted to rejoice together forever.” He was transferred in May to a prison in Berlin. Challenged by his attorney that other Catholics were serving in the army, Franz responded, “I can only act on my own conscience. I do not judge anyone. I can only judge myself.” He continued, “I have considered my family. I have prayed and put myself and my family in God's hands. I know that, if I do what I think God wants me to do, he will take care of my family.” On August 8, 1943, Franz wrote to Fransizka: “Dear wife and mother, I thank you once more from my heart for everything that you have done for me in my lifetime, for all the sacrifices that you have borne for me. I beg you to forgive me if I have hurt or offended you, just as I have forgiven everything…My heartfelt greetings for my dear children. I will surely beg the dear God, if I am permitted to enter heaven soon, that he will set aside a little place in heaven for all of you.” Franz Jägerstätter was beheaded and cremated the following day. In 1946, his ashes were reburied in St. Radegund near a memorial inscribed with his name and the names of almost 60 village men who died during their military service. He was beatified in Linz on October 26, 2007. His “spiritual testament” is now in Rome's St. Bartholomew Church as part of a shrine to 20th-century martyrs for their faith. Blessed Franz's liturgical feast is celebrated on August 9. Want to learn more about Blessed Franz Jägerstätter? Click here! Facebook Twitter Pinterest Email Sign Up for Our Daily Newsletter Includes Saint of the Day, Minute Meditations, and Pause + Pray. Saint of the Day, Copyright Franciscan Media

Contributor: Aaron Lessen, MD Educational Pearls:  Back pain is a common presenting complaint in the emergency department. Challenges arise when tailoring care to elderly populations using standard medical therapy: Muscle relaxants carry the risk of CNS depression or anticholinergic effects such as urinary retention and confusion. Pain medications such as opiates have side effects including constipation, respiratory depression, and hypotension. NSAIDs carry a risk of GI bleeding and worsening kidney function with chronic use. A randomized clinical trial assessing the effects of acupuncture on low back pain took 800 adults aged 65 and older with chronic low back pain and placed them into one of three treatment arms: Usual medical care Standard acupuncture consisting of 8–15 treatment sessions over 12 weeks, plus usual medical care Standard acupuncture consisting of 8–15 treatment sessions over 12 weeks, plus 4-6 maintenance sessions during the next 12 weeks, plus usual medical care Using the Roland-Morris Disability Questionnaire (RMDQ) score, they assessed disability at 6 months and 12 months. The study found that those who had undergone treatment with acupuncture had significantly greater improvements in disability related to low back pain compared to the group that was only treated with usual medical care. Acupuncture is not used in the ER, but could represent a relatively safe adjunctive therapy for patients who are not responding to standard medical therapy alone.   References:  American College of Surgeons Committee on Trauma. Best practices guidelines: geriatric trauma management. American College of Surgeons; 2023. Accessed May 27, 2026. https://www.facs.org/media/ubyj2ubl/best-practices-guidelines-geriatric-trauma.pdf DeBar LL, Wellman RD, Justice M, et al. Acupuncture for chronic low back pain in older adults: a randomized clinical trial. JAMA Netw Open. 2025;8(9):e2531348. doi:10.1001/jamanetworkopen.2025.31348 Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Ahmed Abdel-Hafiz, NREMT-P

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He also reflects on the opportunity with psychedelics, RFK Jr.'s quest to curb SSRI prescriptions, the payer landscape in CNS disorders, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Dr. Hoffman continues his conversation with Dr. Corey Schuler, PhD(c), FNP, DC, CNS, and director of medical affairs at Allergy Research Group.

Dr. Corey Schuler, PhD(c), FNP, DC, CNS, and director of medical affairs at Allergy Research Group, details his paper “Energy Allocation Resilience and Endocrine Integration” in the International Journal of Molecular Sciences. He introduces the Energy Allocation System (EAS), which emphasizes how the body allocates energy—not just produces it—and links many symptoms to impaired bioenergetics and resilience. They discuss mitochondria as energy generators and cellular signaling hubs, the integrated stress response and endocrine coordination (HPA axis, thyroid, gonads), and mitohormesis/eustress (exercise, fasting, heat/cold, circadian “zeitgebers”). Schuler explains nuanced testing for fatigue (diurnal cortisol, CGM patterns, thyroid markers including T3/reverse T3) and a case of a perimenopausal woman where oral contraceptives and cortisol dysregulation affected glucose patterns. They cover mitochondrial support (removing obstacles like pollutants/antibiotics, triglycerides, carnitine, dietary fats, micronutrients) and pacing/sequencing lifestyle interventions.